Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

metreleptin

- PMLiVE

EMA to review safety of Ariad’s Iclusig

Product information will be updated to warn of blood clot risk

Shire Basingstoke

Shire mulls UK job cuts

Enters “employee consultation process” for research site in Basingstoke

- PMLiVE

UCB files Vimpat for expanded epilepsy use

Submits monotherapy application to FDA


- PMLiVE

AZ strikes antibiotic deal with Singapore research unit

Deal with A*STAR to tackle antimicrobial resistance

- PMLiVE

Orphan status for Stem Cell’s leukaemia drug

Tigecycline wins FDA rare disease designation

- PMLiVE

FDA clears Roche’s breakthrough drug Gazyva

First drug approved in US under new scheme

- PMLiVE

FDA suspends sale of Ariad’s cancer drug

Iclusig linked to increased risk of blood clots

- PMLiVE

FDA creates drug shortage plan

Manufacturers required to give early notice of potential shortfall of important medicines

- PMLiVE

AZ names Dunoyer as CFO

He succeeds Simon Lowth as company restructure continues apace

Novartis building

Novartis weighs in on biosimilar naming debate

Files petition urging FDA to keep system where biosimilars share a name with the original drug

- PMLiVE

AZ takes severe asthma antibody into phase III

Benralizumab shows promise in clinical trials

- PMLiVE

FDA raises awareness of misleading drug ads

E-learning course to help HCPS and students learn how to report untruthful promotion

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links